These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Asciminib for the treatment of patients with chronic myeloid leukemia. Cortes J Clin Adv Hematol Oncol; 2021 Apr; 19(4):207-208. PubMed ID: 33989269 [No Abstract] [Full Text] [Related]
4. Platelet function in patients with chronic myeloid leukemia treated with asciminib. Nesr G; Laffan M; Claudiani S; Innes A; Apperley J; Milojkovic D Leuk Lymphoma; 2020 Dec; 61(12):3021-3023. PubMed ID: 32654575 [No Abstract] [Full Text] [Related]
5. Asciminib in chronic myeloid leukemia: many questions still remain to be answered. Eşkazan AE Blood Cancer J; 2021 Apr; 11(4):81. PubMed ID: 33927187 [No Abstract] [Full Text] [Related]
6. Safety and efficacy of asciminib treatment in chronic myeloid leukemia patients in real-life clinical practice. Garcia-Gutiérrez V; Luna A; Alonso-Dominguez JM; Estrada N; Boque C; Xicoy B; Giraldo P; Angona A; Alvarez-Larrán A; Sanchez-Guijo F; Ramírez MJ; Mora E; Vélez P; Rosell A; Colorado Araujo M; Cuevas B; Sagüés M; Cortes M; Encinas MP; Casado Montero LF; Moreno Vega M; Serrano L; Gomez V; Garcia-Hernandez C; Lakhwani S; Paz Coll A; de Paz R; Suarez-Varela S; Fernandez-Ruiz A; Perez Lopez R; Ortiz-Fernández A; Jiménez-Velasco A; Steegmann-Olmedillas JL; Hernández-Boluda JC Blood Cancer J; 2021 Feb; 11(2):16. PubMed ID: 33563899 [No Abstract] [Full Text] [Related]
7. Initial results with asciminib in CML. Romero D Nat Rev Clin Oncol; 2020 Mar; 17(3):135. PubMed ID: 31900441 [No Abstract] [Full Text] [Related]
8. Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1. Schoepfer J; Jahnke W; Berellini G; Buonamici S; Cotesta S; Cowan-Jacob SW; Dodd S; Drueckes P; Fabbro D; Gabriel T; Groell JM; Grotzfeld RM; Hassan AQ; Henry C; Iyer V; Jones D; Lombardo F; Loo A; Manley PW; Pellé X; Rummel G; Salem B; Warmuth M; Wylie AA; Zoller T; Marzinzik AL; Furet P J Med Chem; 2018 Sep; 61(18):8120-8135. PubMed ID: 30137981 [TBL] [Abstract][Full Text] [Related]
9. The outcome of post-transplant asciminib in patients with chronic myeloid leukaemia. Fernando F; Innes AJ; Claudiani S; Pryce A; Hayden C; Byrne J; Gallipoli P; Copland M; Apperley JF; Milojkovic D Bone Marrow Transplant; 2023 Jul; 58(7):826-828. PubMed ID: 37015970 [No Abstract] [Full Text] [Related]
10. Disposition of asciminib, a potent BCR-ABL1 tyrosine kinase inhibitor, in healthy male subjects. Tran P; Hanna I; Eggimann FK; Schoepfer J; Ray T; Zhu B; Wang L; Priess P; Tian X; Hourcade-Potelleret F; Einolf HJ Xenobiotica; 2020 Feb; 50(2):150-169. PubMed ID: 31006307 [TBL] [Abstract][Full Text] [Related]
11. Treatment patterns and clinical outcomes of asciminib in a real-world multiresistant chronic myeloid leukemia patient population. Kockerols CCB; Janssen JJWM; Blijlevens NMA; Klein SK; Van Hussen-Daenen LGM; Van Gorkom GGY; Smit WM; Van Balen P; Biemond BJ; Cruijsen MJ; Corsten MF; Te Boekhorst PAW; Koene HR; Van Sluis GL; Cornelissen JJ; Westerweel PE Haematologica; 2023 Jan; 108(1):240-244. PubMed ID: 36073515 [No Abstract] [Full Text] [Related]
12. Double trouble for CML. Sarosiek K Sci Transl Med; 2017 Apr; 9(384):. PubMed ID: 28381535 [TBL] [Abstract][Full Text] [Related]
13. Axitinib and sorafenib are potent in tyrosine kinase inhibitor resistant chronic myeloid leukemia cells. Halbach S; Hu Z; Gretzmeier C; Ellermann J; Wöhrle FU; Dengjel J; Brummer T Cell Commun Signal; 2016 Feb; 14():6. PubMed ID: 26912052 [TBL] [Abstract][Full Text] [Related]
15. [Tyrosine kinase inhibitors and leukemic stem cells in chronic myeloid leukemia]. Chen SS Zhonghua Xue Ye Xue Za Zhi; 2011 Jul; 32(7):492-6. PubMed ID: 22213876 [No Abstract] [Full Text] [Related]
16. Dual Drug Targeting of Mutant Bcr-Abl Induces Inactive Conformation: New Strategy for the Treatment of Chronic Myeloid Leukemia and Overcoming Monotherapy Resistance. El Rashedy AA; Olotu FA; Soliman MES Chem Biodivers; 2018 Mar; 15(3):e1700533. PubMed ID: 29325229 [TBL] [Abstract][Full Text] [Related]
17. Deregulated expression of Cdc6 as BCR/ABL-dependent survival factor in chronic myeloid leukemia cells. Zhang JH; He YL; Zhu R; Du W; Xiao JH Tumour Biol; 2017 Jun; 39(6):1010428317713394. PubMed ID: 28639894 [TBL] [Abstract][Full Text] [Related]
18. Philadelphia negative BCR-ABL positive chronic myeloid leukemia mimicking juvenile chronic myeloid leukemia in a 2-year-old child. Mahon FX; Labouyrie E; Aurich-Costa J; Dastugue N; Micheau M; Bady C; Perel Y; Bilhou-Nabera C; Reiffers J; Bernard P Leuk Lymphoma; 1997 Aug; 26(5-6):615-9. PubMed ID: 9389369 [TBL] [Abstract][Full Text] [Related]
19. PHA-680626 exhibits anti-proliferative and pro-apoptotic activity on Imatinib-resistant chronic myeloid leukemia cell lines and primary CD34+ cells by inhibition of both Bcr-Abl tyrosine kinase and Aurora kinases. Gontarewicz A; Balabanov S; Keller G; Panse J; Schafhausen P; Bokemeyer C; Fiedler W; Moll J; Brümmendorf TH Leuk Res; 2008 Dec; 32(12):1857-65. PubMed ID: 18514829 [TBL] [Abstract][Full Text] [Related]
20. Frequency of BCR-ABL fusion transcripts in Iranian patients with chronic myeloid leukemia. Yaghmaie M; Ghaffari SH; Ghavamzadeh A; Alimoghaddam K; Jahani M; Mousavi SA; Irvani M; Bahar B; Bibordi I Arch Iran Med; 2008 May; 11(3):247-51. PubMed ID: 18426313 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]